Perth, June 5, 2008 (ABN Newswire) - Helicon Group (ASX:HCG) wishes to inform the market of the release of a third party research report, compiled by Money Cat Consulting, which focuses on the company's core competencies, business model and product acquisitions.
Helicon is a specialty pharmaceutical licensing and marketing company that takes proven proprietary products and drives their market growth in China, the world's fastest growing pharmaceutical market.
The report outlines Helicon's existing product portfolio of Recell(R), Collatamp(R) G, Volplex(R) and Medwrap(TM) Island Wound Dressing with Microban(R), its highly experienced Board and Management, alongside its business strategy that concentrates on high margin pharmaceuticals and a high end target market.
For the full report, in both English and Chinese, please view the link below.
Helicon is listed on the Australian Securities Exchange. The Company's business is to identify and exploit niche market opportunities in the biomedical markets of North Asia, specifically China and to participate in the significant growth that has been projected for these markets over the next 25 years.
Helicon looks for "Special Situations" for advanced Western biopharmaceutical products that are not available in China or other North Asian Markets or where there are market needs that are not being adequately provided for.
Helicon's product partners are likely to be innovative small to medium sized pharmaceutical and healthcare enterprises focused largely on western markets.
Helicon seeks exclusive licenses for the designated markets and utilises a low cost operating overhead base in combination with established channel partners for product registration, distribution, marketing, and sales.
Contact
Peter Abrahamson CEO Mobile: +61-411-336-330 (Australia) Mobile: +86-1366-147-9600 (China) Fax: +61-8-9321-6666 E-mail: peter@helicongroup.com.au www.helicongroup.com.au
Helicon Group Limited
